TGN-020

TGN-020 is a selective Aquaporin 4 (AQP4) inhibitor with an IC₅₀ of 3.1 μM^[1][2]. TGN-020 is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs^[3].TGN-020 alleviates edema and inhibits glial scar formation after spinal cord compression injury in rats^[4]. IC50 & Target: IC50: 3.1 μM (AQP4)^[1] In Vitro: PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins^[3]. In Vivo: TGN-020 (0.02 mg/μL; two microliter intravitreal injections) can suppress retinal edema in STZ-induced diabetic rats (nine-week-old male Wistar rats) retinas^[2].
TGN-020 (100?mg/kg; ip; single dose immediately followed SCI) promotes functional recovery at days 3, 7, 14, 21, and 28, as well as reduces the degree of edema and inhibits the expression of AQP4, GFAP, PCNA at days 3 after SCI. TGN-020 inhibits the glial scar formation and upregulates GAP-43 expression in adult female Sprague-Dawley rats (180-220?g, 9-10?weeks old) with SCI^[4].